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Previewsthe fate of combination therapies using
molecular targeted therapies together
with immune-based manipulations, future
experiments should be performed using
spontaneous tumors in the nontransplan-
tation setting or tumor systems with less
intrinsic immunogenicity. Such combina-
tions may enable the more frequent
induction of long-term durable cancer
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The biological basis of the phenotypic diversity observed in JAK2V617F-positive myeloproliferative
neoplasms is poorly understood. In this issue of Cancer Cell, Chen et al. show that interferon and STAT1
signaling are activated in essential thrombocythemia but not in polycythemia vera. STAT1 promotes mega-
karyopoiesis and thus contributes to an essential thrombocythemia phenotype.Myeloproliferative neoplasms (MPN) are
clonal disorders of hematopoiesis and
are characterized by an accumulation
of mature blood cells. The JAK2V617F-
activating mutation is the most common
molecular abnormality in BCR-ABL-
negative MPN and is present in approxi-
mately 95% of patients with poly-
cythemia vera (PV) and approximately
50% of patients with essential thrombo-
cythemia (ET) and myelofibrosis (Levine
andGilliland, 2008). JAK2 is a cytoplasmic
tyrosine kinase that mediates intracellular
signaling between cell-surface cytokine
receptors and multiple downstream
effector pathways. The V617F mutation
is located in the negative regulatory pseu-
dokinase domain of JAK2 and results in
ligand-independent activation of JAK2
signaling and activation of STAT5 tran-scription (James et al., 2005). JAK2 was
recently found to phosphorylate Tyr41
(Y41) on histone H3 and thus lead to
the release of transcriptional repression
from heterochromatin protein 1a (HP1a)
(Dawson et al., 2009).
In this issue of Cancer Cell, Chen et al.
(Chen et al., 2010) examine how the
JAK2V617Fmutation can lead to different
diseases, PV and ET, with distinct clinical
features. In part, PV is molecularly distinct
from ET because of a higher JAK2V617F
mutational burden in PV patients. Mitotic
recombination of the distal part of chro-
mosome 9p occurs in approximately
one third of PV patients and results in
JAK2V617F homozygosity, whereas mi-
totic recombination almost never occurs
in ET patients (Kralovics et al., 2005).
Chen et al. therefore focused onJAK2V617F heterozygous cells by com-
paring the transcriptional profiles of
erythroid progenitors from patients with
PV or ET to gain insight into the molecular
differences in these diseases.
A key feature of this study is the use
of clonally derived cells for molecular
studies to overcome several technical
challenges in the study of gene expression
in MPN patients and in cancer samples
more generally. The analysis of gene
expression in MPN can be confounded
by the effects of an aberrant micro-
environment, variation in endogenous
cytokine levels, different JAK2V617F
mutational burdens between samples,
genetic heterogeneity within a sample,
and skewing of the differentiation state
within a population of cells in a sample.
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Previewsby analyzing genetically defined clones of
cells. The authors exploited the fact that
JAK2 mutant and wild-type progenitor
cells coexist in the peripheral blood of
JAK2V617F-positive MPN patients. They
cultured peripheral blood mononuclear
cells from JAK2V617F-positive MPN
patients onmethylcellulosemedia supple-
mented with 0.01 U/ml erythropoietin,
a low concentration that the authors found
maximally discriminated between the
expression of PIM1 (a known JAK/STAT
target) in JAK2mutant andwild-type colo-
nies. In a real tour de force, theygrewmore
than 5000 erythroid colonies from 36
JAK2V617F-positive MPN patients (20
ET and 16 PV) and then collected, geno-
typed, and pooled the colonies on the
basis of the JAK2V617Fmutational status.
For each patient, a pool of JAK2V617F
heterozygous erythroid colonies was
compared to a pool of JAK2 WT colonies
via gene expression profiling.
Using this approach, the authors found
that the gene expression profiles of
JAK2V617F mutant colonies were more
closely related to JAK2wild-type colonies
from the same patient than to mutant
colonies from other patients. This sug-
gests that despite the known effects
of JAK2 on histone phosphorylation,
endogenous heterozygous JAK2V617F
expression has modest effects on global
gene expression. Nevertheless, Chen
et al. demonstrate that a gene expression
signature of interferon (IFN) signaling is
preferentially activated in JAK2V617F
heterozygous erythroid progenitors from
ET patients relative to PV patients.
The authors go on to show differential
STAT1 phosphorylation, a known effector
of IFN signaling, in erythroid colonies
from ET patients versus PV patients.
They demonstrate that STAT1 activation
promotes megakaryocytic differentiation,
consistent with the known role of STAT1
in megakaryopoiesis. STAT1 plays a crit-
ical role in the differentiation and poly-
ploidization of megakaryocytes (Huang
et al., 2007). It has been demonstrated
that ectopic expression of STAT1 can
rescue the defects in megakaryocytic
maturation seen in Gata1-deficient
murine megakaryocytes, suggesting that
STAT1 functions downstream of GATA1
(Huang et al., 2007). Interestingly, en-
forced expression of JAK2V617F did not
promote megakaryocytic differentiation
or enhance STAT1 phosphorylation in406 Cancer Cell 18, November 16, 2010 ª20a GATA1-null cell line, suggesting that
GATA1 is required for JAK2V617F-medi-
ated activation of STAT1 (Huang et al.,
2007).
Although Chen et al. report differential
IFN and STAT1 signaling in JAK2V617F
heterozygote ET versus PV erythroid
progenitors, the molecular basis for this
finding remains to be elucidated. The
authors suggest that the development of
divergent phenotypes in JAK2V617F-
positive MPNs occurs as a result of
competition between STAT5 and STAT1
activation; the former would create a bias
toward the development of a PV pheno-
type, and the latter would create a bias
toward an ET phenotype. The observation
that differential signaling occurs in cells
grown under the same experimental
conditions suggests a cell-intrinsic mech-
anism, such as the presence of other
acquired genetic or epigenetic alterations
in addition to JAK2V617F or the presence
of inherited genetic modifiers. Multiple
novel somatic genetic mutations have
been described in MPN patients in the
last few years (Tefferi, 2010), and host
genetic variation has been associated
with differences in MPN phenotype (Par-
danani et al., 2008).
The use of gene expression profiling in
clonally derived cells to compare geno-
typically matched populations might
shed light on other aspects of MPN
biology and the effects of other mutations
in cancer. For example, an important and
still unresolved issue in the MPN field is
the contribution of JAK2V617F gene
dosage to phenotype. JAK2V617F homo-
zygous progenitors occur in the majority
of PV patients, whereas almost all
progenitors in ET patients are JAK2V617F
heterozygous (Scott et al., 2006). Gene
expression profiling of PV homozygote
erythroid progenitors for comparison
with JAK2V617F heterozygote clones
from the same patient could be highly
informative. It is also notable that ET
patients who are JAK2 wild-type have
higher platelet counts and lower hemato-
crit than JAK2V617F mutant ET patients
(Campbell et al., 2005), and expression
profiling of these patients might also be
informative. Identifying reliable gene
expression signatures of kinase muta-
tions in cancer has often proved to be
challenging. The strategy reported by
Chen et al. has the potential to refine
these studies by controllingmany aspects10 Elsevier Inc.of context dependency, pathway activa-
tion by cytokines, and differentiation state
of the cells profiled.
The finding of a previously unrecog-
nized role for IFN and STAT1 signaling in
MPN offers an explanation for the pheno-
typic diversity observed between PV and
ET. The therapeutic implications of this
finding remain to be determined. As the
authors note, the clinical efficacy of IFNa
in both PV and ET patients presents an
apparent paradox with a role for STAT1
activation in ET. It is possible, however,
that the therapeutic efficacy of IFNa is
due to its effects on the bone marrow
microenvironment or on pathways other
than STAT1 or that pharmacologic doses
of IFNa cause exhaustion of the MPN
clone. Differential utilization of STAT path-
ways in MPN could result in distinct
molecular dependencies and novel thera-
peutic opportunities in MPN. Regardless,
transcriptional profiling of clonally derived
cells provides a powerful tool to interro-
gate the consequences of defined molec-
ular abnormalities in MPN and in human
malignancies.
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